INDIANAPOLIS — The U.S. Food and Drug Administration is cracking down on telehealth companies for making “false and misleading” claims about compounded versions of popular weight loss drugs, GLP-1s.
WATCH FULL STORY BELOW
Feds warn telehealth companies about “illegal marketing” of compounded GLP-1s
In a week-long series, WRTV Investigates dug into the benefits and costs associated with these medications.
WRTV Investigates has learned the FDA sent 30 warning letters to telehealth companies for illegally marketing compounded GLP-1s.
Compounded drugs are not FDA-approved, which means the agency does not review their safety, effectiveness or quality before they are marketed…